A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Skyrizi, an interleukin-23 antagonist, is used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It's also used to treat adults with active psoriatic arthritis and moderately to severely active Crohn's disease.
Skyrizi works to inhibit the release of chemicals that can cause inflammation.
Skyrizi is available as a subcutaneous injection-to be injected underneath the skin. Patients may receive prefilled pens, prefilled syringes, or prefilled cartridges:
Use Skyrizi as directed by your doctor. If any questions or concerns arise, talk to your doctor or pharmacist.
The dosage and duration of Skyrizi depends on the condition being treated. Your doctor will tell you how much Skyrizi should be administered and how long your treatment will last. Your doctor will also teach you how to properly inject Skyrizi.
Skyrizi contains risankizumab-rzaa, a humanized immunoglobulin G1 monoclonal antibody. Inactive ingredients are also contained in each prefilled pen, syringe, and cartridge. Refer to the package insert for the full list of inactive ingredients.
Patients who are allergic to risankizumab-rzaa or to any of its excipients should not use Skyrizi.
Skyrizi medication side effects include upper respiratory infections, headache, fatigue, injection site reactions, joint pain, stomach pain, anemia, back pain, fever, joint problems, urinary tract infection, and fungal skin infections; however, these are not all the side effects that can be caused by Skyrizi. If you develop bothersome or persistent side effects, call your doctor right away.
Skyrizi (risankizumab-rzaa). North Chicago, IL: AbbVie Inc.; 2022.